UBE2W expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 2.86370038793393E-10 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.97980000005149E-06 |
Normal-vs-Stage2 |
2.300000E-03 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
1.489530E-02 |
Stage1-vs-Stage2 |
7.632600E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
8.670200E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
7.191800E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
1.12810000230112E-08 |
Normal-vs-AfricanAmerican |
1.786630E-01 |
Normal-vs-Asian |
1.535170E-01 |
Caucasian-vs-AfricanAmerican |
3.427000E-01 |
Caucasian-vs-Asian |
9.098000E-01 |
AfricanAmerican-vs-Asian |
4.361000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
9.50199999999457E-05 |
Normal-vs-Female |
1.24680000002098E-06 |
Male-vs-Female |
3.674200E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
9.535600E-03 |
Normal-vs-Extreme_Weight |
5.61820000000157E-05 |
Normal-vs-Obese |
2.296500E-03 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
4.113600E-01 |
Normal_Weight-vs-Obese |
1.910960E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
4.926400E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.841770E-01 |
Normal-vs-Age(41-60Yrs) |
1.042880E-03 |
Normal-vs-Age(61-80Yrs) |
2.7988999999895E-06 |
Normal-vs-Age(81-100Yrs) |
2.898400E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.344790E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.019800E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.199000E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.268800E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.605200E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.741800E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
1.903230E-01 |
Normal-vs-Grade 3 |
2.234800E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
4.298200E-01 |
Grade 2-vs-Grade 4 |
1.903230E-01 |
Grade 3-vs-Grade 4 |
2.234800E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
1.50239999996415E-07 |
Normal-vs-N1 |
2.041800E-02 |
N0-vs-N1 |
5.826800E-01 |
|
|